Richard Furie Selected Research

belimumab

11/2023	Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial.
8/2023	Clinical Use of Belimumab for Systemic Lupus Erythematosus in the Setting of Advanced Chronic Kidney Disease and End-Stage Kidney Disease on Dialysis: A Case Series.
6/2023	Belimumab treatment of adult idiopathic inflammatory myopathy.
11/2022	Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus.
11/2022	Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study.
10/2022	B cell-targeted therapies in systemic lupus erythematosus.
1/2022	A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.
1/2022	Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.
1/2021	Belimumab in Lupus Nephritis. Reply.
11/2020	Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Richard Furie Research Topics

Disease

35	Systemic Lupus Erythematosus (Libman-Sacks Disease) 04/2024 - 06/2002
17	Lupus Nephritis 03/2024 - 03/2003
7	Herpes Zoster 01/2023 - 02/2014
6	Infections 11/2023 - 02/2014
3	Arthritis (Polyarthritis) 01/2019 - 01/2016
3	Exanthema (Rash) 01/2019 - 01/2016
2	Inflammation (Inflammations) 01/2024 - 10/2022
2	Proteinuria 01/2024 - 02/2014
2	Chronic Kidney Failure (Chronic Renal Failure) 08/2023 - 06/2022
2	Nephritis 11/2022 - 06/2002
2	Neutropenia 01/2022 - 04/2012
2	Fatigue 11/2021 - 01/2014
2	Chronic Disease (Chronic Diseases) 11/2021 - 01/2014
2	Sjogren's Syndrome (Sjogren Syndrome) 11/2020 - 01/2014
2	Rheumatoid Arthritis 10/2016 - 01/2014
1	Wounds and Injuries (Trauma) 01/2024
1	Chronic Renal Insufficiency 08/2023
1	Myositis (Idiopathic Inflammatory Myopathies) 06/2023
1	Asymptomatic Infections 01/2023
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2022
1	Pneumonia (Pneumonitis) 01/2020
1	Bronchitis 01/2020
1	Body Weight (Weight, Body) 01/2020
1	Skin Diseases (Skin Disease) 01/2020
1	Thrombotic Microangiopathies 01/2019
1	Arthralgia (Joint Pain) 01/2019
1	Fever (Fevers) 01/2019
1	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 01/2019
1	Headache (Headaches) 01/2019
1	Crohn Disease (Crohn's Disease) 01/2019
1	Pharyngitis (Sore Throat) 01/2019
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 02/2018
1	Hemolysis 01/2018
1	Bone Marrow Failure Disorders 01/2018
1	Primary Myelofibrosis (Myelosclerosis) 01/2018
1	Human Influenza (Influenza) 01/2017
1	Necrosis 10/2016
1	Rheumatic Diseases (Rheumatism) 10/2016
1	Joint Diseases (Joint Disease) 01/2016
1	Gastroenteritis 02/2014
1	Leukopenia 04/2012
1	Hypotension (Low Blood Pressure) 04/2012
1	Fibrosarcoma 09/2008

Drug/Important Bio-Agent (IBA)

17	belimumabIBA 11/2023 - 01/2008
12	anifrolumabIBA 04/2024 - 01/2016
10	Monoclonal AntibodiesIBA 11/2023 - 06/2002
9	Interferon Type IIBA 04/2024 - 09/2008
7	InterferonsIBA 12/2023 - 11/2016
6	GlucocorticoidsIBA 11/2023 - 02/2014
5	AutoantibodiesIBA 10/2022 - 03/2003
4	Biomarkers (Surrogate Marker)IBA 01/2024 - 10/2016
4	B-Cell Activating FactorIBA 11/2022 - 01/2008
4	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2022 - 04/2012
4	Mycophenolic Acid (Cellcept)FDA LinkGeneric 01/2022 - 04/2012
4	Complement System Proteins (Complement)IBA 01/2019 - 09/2013
2	Adenosine Monophosphate (AMP)IBA 03/2024 - 01/2024
2	CytokinesIBA 10/2022 - 01/2019
2	voclosporinIBA 10/2022 - 11/2020
2	iberdomideIBA 04/2022 - 01/2022
2	Azathioprine (Imuran)FDA LinkGeneric 01/2022 - 01/2020
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 01/2020
2	CreatinineIBA 01/2022 - 02/2014
2	Proteins (Proteins, Gene)FDA Link 01/2022 - 02/2014
2	anti-dsDNA autoantibodyIBA 01/2018 - 03/2003
2	sifalimumabIBA 11/2016 - 01/2016
2	AntibodiesIBA 01/2016 - 01/2014
2	Complement C3 (C3 Complement)IBA 01/2016 - 01/2014
2	Estrogens (Estrogen)FDA Link 01/2014 - 11/2012
2	LigandsIBA 03/2003 - 06/2002
1	Immunosuppressive Agents (Immunosuppressants)IBA 01/2024
1	BI 655064IBA 11/2023
1	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 10/2022
1	Transcription Factors (Transcription Factor)IBA 01/2022
1	fenebrutinibIBA 10/2021
1	Agammaglobulinaemia Tyrosine KinaseIBA 10/2021
1	iscalimabIBA 11/2020
1	ianalumabIBA 11/2020
1	obinutuzumabIBA 11/2020
1	Interferon alpha-beta Receptor (Receptor, Interferon alpha beta)IBA 01/2020
1	eculizumab FDA Link 01/2019
1	Prednisone (Sone)FDA LinkGeneric 01/2019
1	Budesonide (Pulmicort)FDA LinkGeneric 01/2019
1	Ibuprofen (Motrin)FDA LinkGeneric 01/2019
1	Infliximab (Remicade)FDA Link 02/2018
1	Immunologic Factors (Immunomodulators)IBA 02/2018
1	Alprostadil (Muse)FDA LinkGeneric 01/2018
1	Intravenous Immunoglobulins (IVIG)FDA Link 01/2018
1	Tumor Necrosis Factor InhibitorsIBA 10/2016
1	Tacrolimus (Prograf)FDA LinkGeneric 01/2016
1	Calcineurin InhibitorsIBA 01/2016
1	Abatacept (Orencia)FDA Link 02/2014
1	AntigensIBA 01/2014
1	DNA (Deoxyribonucleic Acid)IBA 01/2014
1	complement C4dIBA 01/2014
1	Rituximab (Mabthera)FDA Link 04/2012
1	Aryldialkylphosphatase (Paraoxonase)IBA 09/2008

Therapy/Procedure

18	Therapeutics 01/2024 - 06/2002
1	Investigational Therapies (Experimental Therapy) 11/2020
1	Plasma Exchange 01/2018
1	Drug Tapering 01/2016